



Published in final edited form as:

JOR Spine. 2018 June ; 1(2): . doi:10.1002/jsp2.1014.

Inhibiting tumor necrosis factor-alpha at time of induced intervertebral disc injury limits long-term pain and degeneration in a rat model

Thomas W. Evashwick-Rogler^{#1}, Alon Lai^{#1}, Hironobu Watanabe^{1,2}, Jonathan M. Salandra¹, Beth A. Winkelstein³, Samuel K. Cho¹, Andrew C. Hecht¹, and James C. Iatridis¹

¹Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, New York

²Keiyu Spine Center, Keiyu Orthopedic Hospital, Tatebayashi, Japan

³Departments of Bioengineering and Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania

These authors contributed equally to this work.

Abstract

Background: Painful intervertebral disc (IVD) degeneration has tremendous societal costs and few effective therapies. Intradiscal tumor necrosis factor-alpha (TNF α) is commonly associated with low back pain, but the direct relationship remains unclear.

Purpose: Treatment strategies for low back pain require improved understanding of the complex relationships between pain, intradiscal pro-inflammatory cytokines, and structural IVD degeneration. A rat *in vivo* lumbar IVD puncture model was used to 1) determine the role of TNF α in initiating painful IVD degeneration, and 2) identify statistical relationships between painful behavior, IVD degeneration, and intradiscal pro-inflammatory cytokine expression.

Methods: Lumbar IVDs were punctured anteriorly and injected with TNF α , anti-TNF α , or saline and compared with sham and naive controls. Hindpaw mechanical hyperalgesia was assayed weekly to determine pain over time. 6-weeks post-surgery, animals were sacrificed, and IVD degeneration, IVD height, and intradiscal TNF α and interleukin-1 beta (IL-1 β) expressions were assayed.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Correspondence: James C. Iatridis, Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Place, Box 1188, New York, NY 10029-6574. james.iatridis@mssm.edu.

Conflict of interest

The authors declare no potential conflict of interests.

Author contributions

T.W.E.R. and A.L. were involved in the study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, and critical revisions. H.W. was involved in the study conception and design, acquisition of data, analysis and interpretation of data, and critical revisions. J.M.S. was responsible for the acquisition of data, analysis and interpretation of data, and critical revisions. B.A.W. and S.K.C. were responsible for the analysis and interpretation of data and critical revisions. A.C.H. was involved in the study conception and design, analysis and interpretation of data, and critical revisions. J.C.I. was involved in the study conception and design, analysis and interpretation of data, drafting of manuscript, and critical revisions.

Results: Intradiscal TNF α injection increased pain and IVD degeneration whereas anti-TNF α alleviated pain to sham level. Multivariate step-wise linear regression identified pain threshold was predicted by IVD degeneration and intradiscal TNF α expression. Pain threshold was also linearly associated with IVD height loss and IL-1 β .

Discussion: The significant associations between IVD degeneration, height loss, inflammation, and painful behavior highlight the multifactorial nature of painful IVD degeneration and the challenges to diagnose and treat a specific underlying factor. We concluded that TNF α is an initiator of painful IVD degeneration and its early inhibition can mitigate pain and degeneration. Intradiscal TNF α inhibition following IVD injury may warrant investigation for its potential to alter downstream painful IVD degeneration processes.

Keywords

axial back pain; discogenic pain; disc height; infliximab; intervertebral disc degeneration; low back pain; mechanical hyperalgesia; tumor necrosis factor-alpha

1 | INTRODUCTION

Low back pain has a lifetime prevalence of up to 85% and is the leading cause of disability worldwide.¹⁻³ Intervertebral disc (IVD) degeneration is highly associated with back pain.⁴⁻⁸ However, many patients with magnetic resonance imaging evidence for IVD degeneration do not report back pain,^{9,10} highlighting challenges in diagnosis and treatment. Consequently, nonsurgical interventions are most commonly recommended, and often of limited efficacy.^{11,12} Surgery for disc degeneration has also yielded mixed clinical results. Specific phenotypes of painful IVD degeneration have been introduced to help distinguish aging from painful IVD degeneration conditions, and these phenotypes often involve structural defects and pro-inflammatory conditions.^{4,7,13-16} IVD injuries are known to precipitate a strong pro-inflammatory responses with macrophage infiltration that can induce permanent alterations to IVD structure and function.¹⁷⁻¹⁹ Together, these findings demonstrate that IVD degeneration and pro-inflammatory cytokines play important roles in back pain, but the relationships are complex and nonlinear. A better understanding of the relationship between IVD degeneration and back pain is an important societal research priority, and a clearer understanding may provide insights to identifying therapeutic targets and to developing preventative treatment strategies for discogenic pain.

IVD degeneration-related pain is multifactorial and associated with intradiscal inflammation, neurovascular ingrowth into the IVD, sensitization of nervous system (ie, upregulation of pain-related neuropeptides in the dorsal root ganglia), impingement of adjacent nerve roots, biomechanical instability, and increased demand on the surrounding spinal muscles.²⁰⁻²⁴ In particular, intradiscal pro-inflammatory cytokines tumor necrosis factor-alpha (TNF α) and interleukin-1 beta (IL-1 β) are highly implicated in the development and progression of IVD degeneration and discogenic pain, and these cytokines can be produced by native nucleus pulposus (NP) and annulus fibrosus (AF) cells as well as infiltrating inflammatory cells.^{18,25-34} Upon IVD injury, macrophages and mast cells are recruited and release TNF α and IL-1 β in the IVD and also induce native IVD cells to further produce pro-inflammatory cytokines, including TNF α , IL-1 β , IL-6, and IL-8.³⁵⁻³⁷ TNF α is highly associated with IVD

degeneration because it has been demonstrated to promote extracellular matrix degradation via upregulation of catabolic mediators, including matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS).³⁸⁻⁴⁰ TNF α can also upregulate substance P, nerve growth factor (NGF), and vascular endothelial growth factor production, which may induce painful conditions through sensitization of the nervous system and neurovascular ingrowth into the IVD.⁴¹⁻⁴⁴ The importance of TNF α in discogenic back pain led to multiple human clinical trials treating chronic discogenic pain with TNF α inhibitors, yet results were mixed highlighting a need for further research.⁴⁵⁻⁴⁷ There is a high research priority for investigating a direct relationship between TNF α and discogenic back pain that can further assess contribution of specific pain generators, including intradiscal pro-inflammatory cytokines and structural IVD degeneration, and such a controlled investigation requires an animal study.

Animal models are commonly used for studying IVD degeneration, with pain often used as motivation for studying IVD degeneration. *In vivo* rodent models play an important role in determining the underlying pathophysiology of painful IVD degeneration because known quantitative methods are available that can characterize specific painful responses.^{24,48} However, few studies have directly assessed the pain associated with IVD degeneration, and no study to date has investigated the direct associations between pain, structural degeneration, and intradiscal pro-inflammatory cytokines in order to characterize the most important contributors to the painful process. Furthermore, rats offer advantages over mice because the larger size enables more precise control of induced injuries. Annular injury models (using puncture or stab injury) are commonly adopted to induce IVD degeneration in rat models because the severity of injury can be controlled. Our group previously developed an *in vivo* painful IVD degeneration model in rat and showed that AF puncture with intradiscal injection of phosphate buffered saline (PBS) produced painful behavior and degeneration in the injured IVDs, and intradiscal injection of TNF α into the injured IVD further increased painful behavior up to 6 weeks post-injury.^{48,49} The findings suggested that TNF α plays an important role in the development of IVD degeneration-related pain; however, it is unclear whether inhibiting TNF α at the time of IVD injury can prevent or mitigate IVD degeneration and degeneration-related pain. Furthermore, the relationships between pain, intradiscal pro-inflammatory cytokines, and IVD structural degeneration in this model are unknown.

This study applied an *in vivo* rat model of painful IVD degeneration to determine (1) a role of TNF α in causing painful IVD degeneration following an IVD puncture injury; and (2) the relationships between pain, IVD structural degeneration, and intradiscal pro-inflammatory cytokines in this model. We hypothesized that annular injury with intradiscal administration of TNF α would increase painful IVD degeneration, whereas blocking TNF α at the time of injury with intradiscal injection of anti-TNF α would prevent this painful IVD degeneration cascade. We also hypothesized that the painful behavior would be multifactorial but be predicted by intradiscal pro-inflammatory cytokines expression and IVD structural degeneration.

2 | MATERIALS AND METHODS

2.1 | Experimental design

A total of 36 skeletally mature⁵⁰ male Sprague-Dawley rats (4-5 months old) were used and randomly assigned into one of five experimental groups: naive ($n = 8$), sham ($n = 8$), PBS ($n = 8$), TNF α ($n = 6$), or anti-TNF α ($n = 6$). In the PBS, TNF α , and anti-TNF α groups, rat lumbar IVDs were exposed, punctured, and intradiscally injected with PBS, TNF α , or anti-TNF α , respectively. The injection of TNF α aimed to further increase the content of intradiscal TNF α in addition to the expected inflammatory response resulting from IVD injury; while anti-TNF α was injected to downregulate the intradiscal TNF α response induced by IVD injury. The sham group involved surgery to expose lumbar IVDs only without puncture or injection, and naive group involved no surgical procedures at all. Pain behavior and IVD height were measured before surgery and then weekly after surgery using hindpaw mechanical hyperalgesia test and lateral radiographs, respectively. After pain behavior and radiographic measurements were taken at the 6-week time point, the rats were euthanized, and the lumbar spines were isolated for morphological and biochemical analyses. All experimental procedures were approved by the Institutional Animal Care and Use Committee.

2.2 | Lumbar IVD puncture and injection injury

Surgery was performed under sterile conditions and general anesthesia (2% isoflurane in oxygen). The lumbar spine was accessed via an anterior approach with an abdominal midline incision. The lumbar spine was visualized, and the IVD levels were identified using the pelvic rim and aortic bifurcation as anatomical landmarks. L3/4, L4/5, and L5/6 IVDs were then punctured along the midline with a 26-gauge needle at a depth of 3.0 mm guided by a needle stopper followed by intradiscal injection of PBS (2.5 μ L), TNF α (0.25 ng in 2.5 μ L; 80045RNAE50; Sino Biological Inc., Beijing, China),⁴⁹ or anti-TNF α (2.5 μ L, 0.5 mg/kg; Remicade; Janssen Biotech Inc., Horsham, Pennsylvania),⁵¹ for PBS, TNF α , and anti-TNF α groups, respectively, with all three IVDs receiving the same injectate (Figure 1). The anti-TNF α agent, infliximab, is a monoclonal antibody that binds with high specificity to soluble and transmembrane TNF α and prevents TNF α from binding to its receptor thereby blocking its pro-inflammatory effects. The peritoneum was then closed with 3-0 silk sutures, and the skin was closed with 4-0 nylon sutures. Rats were allowed *ad libitum* access to food and water. Rats were closely monitored for complications. Volume and method of intradiscal injection were determined from preliminary *in vitro* and *in vivo* studies demonstrating no visible fluid leakage or nerve irritation.

2.3 | Pain behavior measurement

Severity of pain was measured using hindpaw mechanical hyperalgesia test, shown to be a sensitive measurement technique to quantify the pain associated with IVD degeneration in rats.⁴⁸ A decrease in paw withdrawal threshold indicated an increase in pain sensitivity. The test was carried out in wire mesh-floored cages, and the rats were placed in the cages at least 20 min prior to measurement for acclimation. Calibrated von Frey filaments, ranging from 0.4 to 26.0 g (Stoelting, Wood Dale, Illinois), were then applied to the plantar surface of the hindpaw with sufficient force to cause buckling of the filament. The 50% paw withdrawal

thresholds were determined for both left and right hindpaws using the up-down method with three trials for each side.⁵² The withdrawal thresholds from left and right hindpaws were then averaged for analysis and normalized to preoperative values.

2.4 | Radiographic IVD height measurement

IVD heights of noninjured IVD (ie, L2/3 IVD) and injured IVDs (i.e. L4/5 and L5/6 IVDs) were measured via lateral radiographs with the animals under general anesthesia. Animals were anesthetized for approximately 10 min before taking the radiographs to minimize the effect of anesthesia on IVD height resulting from muscle relaxation and IVD swelling.⁵³ After the radiographic film was digitized using a flatbed scanner with backlighting, the image was magnified and analyzed in ImageJ. Both upper and lower vertebral boundaries of the motion segment were manually identified, and coordinates of the vertebral boundaries were obtained. The coordinates were then transferred to the MATLAB (Mathworks, Inc., Natick, Massachusetts),⁴⁹ which measured the averaged distance between the vertebral boundaries. A step wedge was used as a scale reference. Each disc was measured thrice and averaged for analysis. The IVD heights from the injured IVDs were also averaged for analysis and normalized by dividing by the presurgical heights of each IVD. Interrater and intrarater reliability tests were used to determine the consistency and repeatability for measuring IVD height using this technique. A total of 30 IVDs were randomly picked and measured by three researchers on two separate days with 7 days apart. The interrater reliability was excellent with intraclass correlation coefficient, ICC(3,3), of 0.983; and the intrarater reliability was also excellent with ICC(3,3) for the three researchers of 0.992, 0.993, and 0.977 for the three researchers, respectively.

2.5 | Tissue harvesting

Rats were euthanized at 6 weeks after surgery via carbon dioxide inhalation. Immediately after sacrifice, the lumbar spine (L1/2-L3/4) was harvested, fixed in formalin, decalcified, embedded, and sectioned sagittally at 5 μ m intervals.

2.6 | IVD morphology and semi-quantitative degeneration grading

Mid-sagittal sections were stained with safranin-O/light green/hematoxylin to assess IVD morphology and evaluated using bright-field microscopy. The severity of IVD degeneration of each section was assessed using a semi-quantitative IVD degeneration grading scale adapted from the grading scales proposed by Masuda et al⁵⁴ and Rutges et al.⁵⁵ The combined degeneration scale consisted of five categories, including (1) AF, (2) border between AF and NP, (3) cellularity of NP, (4) matrix of NP, and (5) endplate (Table 1). Each category received a score of 0-2 with score 0 for normal morphology and score 2 for characteristic severe degeneration; therefore, the overall degenerative score for each section was between 0 and 10. All sections were assessed by two researchers blinded to the experimental groups. Intra- and inter-rater reliability scores were obtained for error analysis purposes. Interrater reliability was excellent with intraclass correlation coefficient, ICC(1,3), for the two researchers of 0.961 and 0.968; and intrarater reliability was excellent with intraclass correlation coefficient, ICC(1,3), of 0.887. Each section was graded twice at least 2 weeks apart by each researcher, and the four grades were then averaged for analysis.

2.7 | Intradiscal pro-inflammatory cytokine expressions

Expression of intradiscal pro-inflammatory cytokines TNF α and IL-1 β was determined using immunohistochemistry. Mid-sagittal IVD sections were selected from each rat. Sections were rehydrated, treated with protein block reagent, and incubated overnight with either rabbit polyclonal primary antibody against rat TNF α (NB600-587; Novus, Littleton, Colorado), rabbit polyclonal primary antibody against rat IL-1 β (bs-6319R; Bioss, Woburn, Massachusetts), or normal rabbit serum (Biocare Medical, Concord, California) as negative control. Sections were incubated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody (MP-7451, ImmPRESS VR Reagent; Vector Laboratories, Burlingame, California) for 30 min and 3% hydrogen peroxide for 10 min, then treated with diaminobenzidine-based horseradish-peroxidase substrate (ImmPACT DAB; Vector Laboratories) to visualize the immunoreactivity. Sections were counterstained with toluidine blue, dehydrated, mounted, and evaluated using bright-field microscopy.

Nine area-of-interest regions were identified from each IVD section, including outer anterior AF (three), inner anterior AF (two), NP (two), and posterior AF (two). The percentage of immunopositive cells from each area-of-interest region was determined via manual cell counting and then averaged for analysis.

2.8 | Statistical analysis

The results of hindpaw mechanical hyperalgesia and IVD height obtained at different time points were normalized to those obtained before surgery to minimize interanimal variability, and the changes of the normalized results with time within and across experimental groups were analyzed using two-way repeated measures ANOVA with Tukey's test as post hoc comparison. The morphological degeneration grades as well as percentages of intradiscal TNF α and IL-1 β immunopositive cells across experimental groups were compared using one-way ANOVA with Tukey's test as post hoc comparison. The correlation between paw withdrawal threshold, IVD height, IVD degeneration grade, and percentage intradiscal TNF α and IL-1 β immunopositivities were analyzed using Pearson's correlation. A multivariate stepwise linear regression analysis was used to determine the predictive factors for paw withdrawal threshold, where all other outcome measures were defined as the independent variables. All the statistical analyses were conducted using Prism version 7 (GraphPad Software, Inc., La Jolla, California) and SPSS Statistics version 22 (IBM Corporation, Armonk, New York), and the level of significance was set to 0.05. D'Agostino and Pearson test demonstrated all data were normally distributed, so parametric tests were performed for data analyses.

3 | RESULTS

3.1 | Surgery did not affect rat general health

Both sham surgery and spinal injury procedures were well-tolerated by the rats. The rat mean \pm SD body weight of 495 \pm 48 g, 504 \pm 52 g, 522 \pm 51 g, 533 \pm 52 g, 544 \pm 53 g, 555 \pm 53 g, and 565 \pm 55 g, for presurgery and postsurgery weeks 1, 2, 3, 4, 5, and 6, respectively. There were no significant differences between groups at any time point. No intraoperative

complications or obvious stress or discomfort were observed from the general physical examination.

3.2 | TNF α inhibition at time of IVD injury prevents development of acute and long-term painful behavior

The continuous changes of normalized hindpaw withdrawal threshold within each group, as well as the comparison of withdrawal threshold across groups at acute (ie, 1-week postsurgery) and long-term (ie, 6-week postsurgery) were documented (Figure 2). Paw withdrawal thresholds were normalized to pre-op levels for each animal. There were no significant changes in hindpaw withdrawal thresholds among naive and sham animals across the 6-week duration of the study (Figure 2A). The paw withdrawal thresholds were significantly decreased following TNF α and PBS injections, and maintained throughout the duration of the 6-week study ($P < .05$ at all time points compared to presurgery, Figure 2A). Their withdrawal thresholds were lower than both naive and sham groups for both 1-week and 6-week time points ($P < .05$, Figure 2B,C, respectively). However, intradiscal injection of anti-TNF α prevented the decrease in paw withdrawal threshold induced by IVD injury and did not show significant change across the 6-week duration of the study ($P > .05$ compared to presurgery for all time points). Paw withdrawal thresholds following anti-TNF α injection were significantly higher than following both PBS and TNF α injections at both 1-week and 6-week time points ($P < .05$ with both groups at both time points).

3.3 | TNF α inhibition at time of IVD injury prevents IVD structural degeneration but not height loss

Normal IVD morphology was observed in both naive and sham animals. AF puncture with intradiscal injections of PBS, TNF α , or anti-TNF α induced observable degenerative changes, including smaller and more fibrous NP, decreased number of NP cells, less distinct NP-AF boundary, and disorganized AF lamellae (Figure 3A). There was no evidence of NP herniation in any IVD upon histological analysis.

The semi-quantitative degeneration grading scale showed that both naive and sham IVDs had minimal degeneration with mean \pm SD degeneration grade of 1.25 ± 0.74 and 2.09 ± 1.97 , respectively (Figure 3B). PBS-injected (5.72 ± 2.57) and TNF α -injected (7.60 ± 1.39) IVDs had significantly increased degeneration than both naive and sham IVDs and some evidence of increased glycosaminoglycan loss. Anti-TNF α -injected (2.90 ± 2.93) IVDs had significantly lower degeneration than TNF α -injected IVDs but did not show significant difference from naive-, sham-, or PBS-injected IVDs ($P = .615$, $P = .955$, and $P = .133$, respectively).

The IVD heights obtained at 6-week postsurgery were normalized to presurgery baseline. The normalized heights of all injured IVDs (including PBS, TNF α , and anti-TNF α) were significantly smaller than those of naive and sham IVDs (Figure 3B). There was no significant difference between naive and sham groups, or among the three injury groups (Figure 3C).

3.4 | TNF α inhibition at time of IVD injury prevents long-term upregulation of intradiscal TNF α

At 6-week postsurgery, compared to naive and sham IVDs, the percentage of intradiscal TNF α immunopositive cells was increased following PBS or TNF α injections. However, intradiscal injection of anti-TNF α alleviated the changes in intradiscal TNF α immunopositivity induced by IVD injury and showed no significant difference from both naive or sham IVDs (Figure 4E).

In contrast, the percentage of intradiscal IL-1 β immunopositive cells was only increased following PBS injection relative to sham at 6-week postsurgery. IL-1 β trends to increase in TNF α -injected IVDs relative to sham. The anti-TNF α -injected IVDs did not show significant difference in intradiscal IL-1 β immunopositivity from both naive or sham IVDs (Figure 4F).

3.5 | Painful behavior predicted by IVD degeneration using stepwise linear regression analysis

Multivariate stepwise linear regression analysis showed that the normalized paw withdrawal threshold could be significantly predicted by IVD degeneration grade ($\beta = -0.533$, $P = .001$) and intradiscal TNF α immunopositivity ($\beta = -0.355$, $P = .016$) (Table 2). Normalized paw withdrawal threshold was also linearly correlated to IVD degeneration grade and intradiscal TNF α and IL-1 β immunopositivity with R^2 of 0.481, 0.315, and 0.204, respectively (Figure 5A-C). IVD degeneration grade correlated with intradiscal TNF α and IL-1 β immunopositivity with R^2 of 0.226 and 0.123, respectively (Figure 5D,E). Intradiscal TNF α and IL-1 β immunopositivity with R^2 of 0.453 (Figure 5F).

3.6 | Pain threshold, structural degeneration and intradiscal pro-inflammatory cytokines correlate with each other

Pearson's correlation analysis showed that the normalized paw withdrawal threshold, IVD degeneration grade, normalized IVD height, as well as intradiscal TNF α and IL-1 β immunopositivity were significantly correlated with each other ($P < .05$), except for the association between IVD degeneration and intradiscal IL-1 β expression, which showed a trend of correlation with R^2 of 0.351 ($P = .053$) (Table 3).

4 | DISCUSSION

This study identified multifactorial causes of painful IVD degeneration and determined a causal role for TNF α on the initiation of painful IVD degeneration in an *in vivo* rat IVD puncture and injection model. Intradiscal TNF α was directly and causally involved in the initiation of a painful IVD degeneration cascade because anti-TNF α injection into lumbar IVDs at the time of IVD puncture injury reduced pain and IVD degeneration grade to sham levels. IVD degeneration grade and intradiscal TNF α expression were identified as predictive factors for IVD degeneration-related pain using stepwise multivariate regression, while univariate correlation analysis further identified associations of pain with IVD height loss and intradiscal IL-1 β expression.

This study injected anti-TNF α intradiscally at the time of injury and identified TNF α as an essential initiator of a painful IVD degeneration cascade. Relatively few animal models exist that identify causative factors underlying painful IVD degeneration without direct herniation. Annular puncture with intradiscal injection of TNF α previously demonstrated significantly increased IVD degeneration and increased painful behavior, similar to the current study which showed enhanced pain sensitivity behavior with either TNF α or PBS injection.⁴⁹ Intradiscal injection of complete Freund's adjuvant into the rat lumbar IVD also significantly increased painful behavior in rats *in vivo* as measured by the hindpaw mechanical hyperalgesia test.⁵⁶ Both of these studies implicate TNF α and intradiscal pro-inflammatory cytokines more generally as sufficient to initiate a painful IVD degeneration cascade, yet neither determined if TNF α was an essential initiator of the painful IVD degeneration. Taken together with the literature, the results from this study suggest local TNF α inhibition at early stages after IVD injury may offer potential benefit for preventing painful IVD degeneration progression, although immediate intradiscal injection of anti-TNF α would be difficult to directly translate to the human clinical condition.

The moderate to severe IVD degeneration of the current study is comparable to other injury models in the literature. Previous puncture injury studies demonstrated that IVD degeneration occurs with needle puncture, and IVD degeneration severity increased with needle diameter and needle puncture depth.^{49,54,57-59} Needle puncture injuries with complete AF puncture (ie, into the NP) with larger needle diameters (~50% IVD height) induced moderate to severe IVD degeneration, similar to the current study. Multiple studies also inject pro-inflammatory factors or matrix degrading enzymes to induce matrix changes more representative of chronic degeneration conditions in acute puncture injury models. Specifically, annular puncture with chondroitinase ABC, complete Freund's adjuvant, and TNF α have all been used to induce moderate to severe IVD degeneration with significantly reduced IVD height, diminished proteoglycan content, loss of NP cells, and altered IVD biomechanics.^{49,56,60,61} While these studies contextualize the current model of painful IVD degeneration as a model of moderate to severe IVD degeneration, several comprehensive reviews of other animal models of IVD degeneration exist.^{24,62-64}

TNF α inhibition has been studied clinically for treating low back pain; however, the effects are inconclusive. Patient-reported levels of pain and disability were decreased up to 8 weeks after intradiscal administration of the TNF α inhibitor etanercept (2 mL bupivacaine with 10 mg etanercept) in a prospective, randomized clinical trial.⁴⁵ Similar findings were observed in a retrospective analysis, which showed perispinal delivery of etanercept (25 mg) significantly reduced pain and weakness in patients with severe, chronic discogenic pain.⁴⁶ However, another study found no reduction in patient-reported pain 1-month after intradiscal etanercept administration in a double-blind placebo-controlled study.⁴⁷ The current findings in the context of the more mixed human clinical literature suggest that TNF α inhibition immediately after acute, traumatic IVD injury, or possibly early in the IVD degenerative process offers promise for mitigating a painful degenerative cascade. We speculate the limited effectiveness of TNF α inhibition in clinical studies may be the result of administration long after the onset of discogenic pain, so the timing of anti-TNF α administration is of utmost importance. Future studies using the current animal model are warranted to determine the importance of TNF α inhibition timing, specifically whether

intradiscal anti-TNF α injection can reduce pain after the onset of painful IVD degeneration. However, we also provided local treatment at the source of pain in this model and it is possible that some of the limited efficacy of the clinical trials is due to ineffective dosing at the source of the pain. Further investigations are also warranted to assess dosing effects and administration routes, and to investigate TNF α inhibition in chronic painful IVD degeneration conditions clinically.

In this *in vivo* rat study, the pain behavior was significantly associated with IVD degeneration and intradiscal TNF α expression as predictive factors using multivariate stepwise linear regression, and univariate correlation analysis also showed that the pain was significantly associated with loss of IVD height and intradiscal IL-1 β expression. These results are consistent with another study that used an annular puncture model with NP removal that found a correlation between IVD degeneration and mechanical hyperalgesia, which was assayed directly on the low back.⁶⁵ The multiple associations of pain with IVD structural and biochemical degenerative changes in this *in vivo* rat model have many similarities with painful IVD degeneration in humans, which supports the feasibility of using this rat model to understand the pathophysiology of discogenic pain.^{4,6,13,66-68} The lack of significant herniation or endplate damage in the observed IVD degeneration in this study is suggestive of intradiscal pro-inflammatory cytokines as a cause for pain. It should be noted that anti-TNF α prevented IVD degeneration but not a loss of IVD height. We believe this is because anti-TNF α mitigated some of the inflammation-induced matrix catabolism, as observed by decreased IVD degeneration, but did not restore the IVD height loss caused by the puncture.

We chose to study the role of TNF α in initiating discogenic pain and the effect of its inhibition because it is thought to initiate an inflammatory cascade, which is then propagated by other pro-inflammatory cytokines. TNF α stimulates IL-1 β expression, which plays a significant role in upregulating catabolic MMPs and ADAMTS enzymes.^{38,69-71} Bovine IVDs cultured in the presence of TNF α had increased gene expression of multiple pro-inflammatory and catabolic factors after 7 days, which persisted to 21 days without recovery after TNF α was removed from culture.⁷⁰ Similarly, human NP cells cultured with TNF α increased gene expression of IL-1 β , IL-6, and IL-8, which was inhibited by early anti-TNF α administration.⁷² Interestingly, human NP cells cultured with TNF α significantly upregulated IL-1 β gene expression, and NP cells treated with IL-1 β significantly upregulated MMPs to a much greater extent than when treated with TNF α ,⁶⁹ further highlighting the role of TNF α in inflammation initiation and of IL-1 β in enhancing catabolism. Accordingly, we believed inhibiting specifically TNF α at the time of annular injury would have the greatest effect on the inflammatory response, which the current data support. This study adds to the literature by showing that TNF α plays a key role in initiating a painful inflammatory cascade, which early inhibition can prevent. A previous clinical study found the serum half-life of infliximab, the TNF α inhibitor used in this study, is 7 to 12 days when given intravenously.⁷³ While the IVD is avascular and infliximab may have remained in the IVD for a longer period of time, it is highly unlikely that the original infliximab remained present at the 6-week end point. Thus, the significant decrease in intradiscal TNF α after intradiscal anti-TNF α injection suggested that intradiscal anti-TNF α

administration was effective in inhibiting the inflammatory cascade in response to IVD puncture injury.

Furthermore, TNF α and intradiscal pro-inflammatory cytokines more generally are known to be associated with multiple pain pathways.^{16,27,33,34,74,75} TNF α can induce inflammatory pain as it directly sensitizes sensory neurons through a reduction in the firing thresholds, which contributes to maintenance of pain.⁷⁶⁻⁸¹ An electrophysiology study demonstrated TNF α application to rat nociceptive neurons decreased response latency and increased spontaneous firing frequency, supporting the role of TNF α sensitizing peripheral nerves on the cellular level.⁷⁶ TNF α has also been shown to induce pain on the behavioral level. TNF α injection directly into rat hindpaws resulted in increased hyperalgesia demonstrating a role of TNF α in the initiation of inflammatory pain, and this painful behavior was inhibited by local TNF α inhibition, demonstrating the potential of local TNF α inhibition to alleviate the inflammatory pain in the periphery.⁸² In an investigation of the inflammatory response and effect of anti-TNF α on pain in a surgically induced IVD herniation model with autologous IVD autograft and spinal nerve ligation, local application of anti-TNF α at the time of herniation surgery significantly improved paw withdrawal threshold in a rat model.³⁷ These findings further support the role of TNF α in peripheral inflammatory pain and the concept of locally inhibiting TNF α at early stages after injury to prevent the development of long-term pain. However, it should be noted that the pain pathophysiology is different between the two models. The pain pathophysiology is much clearer in IVD herniation models with inflamed IVD tissue directly impinging a nerve but more difficult to identify in discogenic pain models, which highlights the importance of the validation in the current model. TNF α upregulates NGF in IVD cells, and nociceptive nerves, usually restricted to the outer AF in normal healthy IVDs, can be stimulated with NGF to grow into the inner AF and NP as was found in the painful human IVDs.^{23,41,83,84} In this model, anti-TNF α may have worked in several different ways: mitigating intradiscal inflammation, thereby preventing innervated nerve stimulation, decreasing the inflammatory environment of adjacent nerve roots, or inhibiting neovascular innervation. Likely, the mitigation of pain behavior following annular injury is a combination of the aforementioned factors, and the specific mechanism requires future investigations. However, histological assessments with this model did not identify obvious nerves or vessels, suggesting neovascularization is not likely to be a dominant cause of observed pain.

The current study focused on the changes in painful behavior and the structural and biochemical changes in the IVD in response to IVD injury and was limited because we did not investigate changes in the central nervous system, which plays important roles in both acute and chronic pain and warrants future investigation. Previous work has shown TNF α upregulates NGF in NP and AF cells in vitro,⁴¹ so annular puncture with intradiscal injections of TNF α or PBS may facilitate nerve ingrowth and upregulation of neurotrophic factors including NGF and VEGF, while anti-TNF α injection mitigates nerve ingrowth and expression of these neurotrophic factors. Similarly, local anti-NGF treatment attenuated the development of mechanical hyperalgesia in a rat facet joint distraction model,⁸⁵ so there is some evidence to support TNF α and NGF play important roles on pain initiation. Understanding the relationship of other inflammation-related proteins and NGF to pain and the broader inflammatory changes after TNF α injection or inhibition is an interesting area of

future investigation. Additionally, only male rats were used in this study to minimize variability in behavioral and biochemical measurements, and it should be noted that there is evidence that pain pathways differ between sexes.^{86,87} While it is not expected that the conclusions of the current findings would differ across sexes, male and female rats likely have sex differences in the neural pathophysiology of painful IVD degeneration that warrant further investigation. Lastly, rodent IVDs contain different cell types to those during human degeneration, and thus the responses may vary. Nonetheless, rodents are widely used to study IVD pathologies and treatment strategies.⁸⁸

In conclusion, the results demonstrate that intradiscal TNF α plays a critical role initiating an inflammatory cascade that results in painful IVD degeneration and suggest that inhibiting TNF α at early stages after IVD injury may offer potential benefit for preventing pain symptoms and structural IVD degeneration. The pain behavior following IVD injury was significantly associated with IVD degeneration and intradiscal pro-inflammatory cytokine expressions, which supports that this *in vivo* rat model has a phenotype similar to the human condition of painful IVD degeneration and could be a useful tool to study the underlying pathophysiology of painful IVD degeneration and for screening therapeutic strategies for discogenic pain.

ACKNOWLEDGEMENTS

Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers R01AR064157 & R01AR057397 (Iatridis, PI) and in part by the Botanical Center for Promotion of Cognitive and Psychological Resilience as supported by the National Center for Complementary and Integrative Health of the National Institutes of Health under Award Number P50AT008661 (Pasinetti, PD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. S.K.C. receives grant funding from Zimmer Biomet on projects unrelated to the current study and is a consultant for Zimmer Biomet, Stryker, Medtronic, and DePuy Synthes on projects unrelated to the current study. A.C.H. is a consultant for Zimmer Spine and Medtronic on projects unrelated to the current study.

REFERENCES

1. Walker BF. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. *J Spinal Disord.* 2000; 13(3):205–217. [PubMed: 10872758]
2. Hoy D, March L, Brooks P. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis.* 2014; 73(6):968–974. [PubMed: 24665116]
3. Vos T, Flaxman AD, Naghavi M. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380(9859):2163–2196. [PubMed: 23245607]
4. Cheung KMC, Karppinen J, Chan D. Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. *Spine.* 2009; 34(9):934–940. [PubMed: 19532001]
5. De Schepper EIT, Damen J, van Meurs JBJ. The association between lumbar disc degeneration and low back pain: the influence of age, gender, and individual radiographic features. *Spine.* 2010; 35(5):531–536. [PubMed: 20147869]
6. Livshits G, Popham M, Malkin I. Lumbar disc degeneration and genetic factors are the main risk factors for low back pain in women: the UK Twin Spine Study. *Ann Rheum Dis.* 2011; 70(10): 1740–1745. [PubMed: 21646416]
7. Adams MA, Dolan P. Intervertebral disc degeneration: evidence for two distinct phenotypes. *J Anat.* 2012; 221(6):497–506. [PubMed: 22881295]

8. Ito K, Creemers L. Mechanisms of intervertebral disk degeneration/injury and pain: a review. *Global Spine J.* 2013; 3(3):145–152. [PubMed: 24436865]
9. Boden SD, Davis DO, Dina TS, Patronas NJ, Wiesel SW. Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation. *J Bone Joint Surg Am.* 1990; 72(3):403–408. [PubMed: 2312537]
10. Savage RA, Whitehouse GH, Roberts N. The relationship between the magnetic resonance imaging appearance of the lumbar spine and low back pain, age and occupation in males. *Eur Spine J.* 1997; 6(2):106–114. [PubMed: 9209878]
11. Qaseem A, Wilt TJ, McLean RM. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 2017; 166(7):514–530. [PubMed: 28192789]
12. Lu Y, Guzman JZ, Purmessur D. Nonoperative management of discogenic back pain: a systematic review. *Spine.* 2014; 39(16):1314–1324. [PubMed: 24827515]
13. Cheung KMC, Samartzis D, Karppinen J, Luk KDK. Are “patterns” of lumbar disc degeneration associated with low back pain?: new insights based on skipped level disc pathology. *Spine.* 2012; 37(7):E430–E438. [PubMed: 22466575]
14. Iatridis JC, Nicoll SB, Michalek AJ, Walter BA, Gupta MS. Role of biomechanics in intervertebral disc degeneration and regenerative therapies: what needs repairing in the disc and what are promising biomaterials for its repair? *Spine J.* 2013; 13(3):243–262. [PubMed: 23369494]
15. Weber KT, Alipui DO, Sison CP. Serum levels of the proinflammatory cytokine interleukin-6 vary based on diagnoses in individuals with lumbar intervertebral disc diseases. *Arthritis Res Ther.* 2016; 18:3. [PubMed: 26743937]
16. Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. *Nat Rev Rheumatol.* 2014; 10(1):44–56. [PubMed: 24166242]
17. Nakazawa KR, Walter BA, Laudier DM. Accumulation and localization of macrophage phenotypes with human intervertebral disc degeneration. *Spine J.* 2018; 18(2):343–356. [PubMed: 29031872]
18. Ulrich JA, Liebenberg EC, Thuillier DU, Lotz JC. ISSLS prize winner: repeated disc injury causes persistent inflammation. *Spine.* 2007; 32(25):2812–2819. [PubMed: 18246002]
19. Walter BA, Likhitpanichkul M, Illien-Junger S, Roughley PJ, Hecht AC, Iatridis JC. TNF α transport induced by dynamic loading alters biomechanics of intact intervertebral discs. *PLoS One.* 2015; 10(3):e0118358. [PubMed: 25734788]
20. Brisby H. Pathology and possible mechanisms of nervous system response to disc degeneration. *J Bone Joint Surg Am.* 2006; 88(suppl 2):68–71. [PubMed: 16595447]
21. Faustmann PM. Neuroanatomic basis for discogenic pain. *Z Orthop Ihre Grenzgeb.* 2004; 142(6):706–708. [PubMed: 15614652]
22. Freemont AJ, Peacock TE, Goupille P, Hoyland JA, O’Brien J, Jayson MIV. Nerve ingrowth into diseased intervertebral disc in chronic back pain. *Lancet.* 1997; 350(9072):178–181. [PubMed: 9250186]
23. Freemont AJ, Watkins A, Le Maitre C. Nerve growth factor expression and innervation of the painful intervertebral disc. *J Pathol.* 2002; 197(3):286–292. [PubMed: 12115873]
24. Mosley GE, Evashwick-Rogler TW, Lai A, Iatridis JC. Looking beyond the intervertebral disc: the need for behavioral assays in models of discogenic pain. *Ann N Y Acad Sci.* 2017; 1409(1):51–66. [PubMed: 28797134]
25. Yoshida M, Nakamura T, Sei A, Kikuchi T, Takagi K, Matsukawa A. Intervertebral disc cells produce tumor necrosis factor alpha, interleukin-1 beta, and monocyte chemoattractant protein-1 immediately after herniation: an experimental study using a new hernia model. *Spine.* 2005; 30(1):55–61. [PubMed: 15626982]
26. Miyagi M, Ishikawa T, Orita S. Disk injury in rats produces persistent increases in pain-related neuropeptides in dorsal root ganglia and spinal cord glia but only transient increases in inflammatory mediators: pathomechanism of chronic discogenic low back pain. *Spine.* 2011; 36(26):2260–2266. [PubMed: 21228748]
27. Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1 β and TNF α expression profile. *Arthritis Res Ther.* 2007; 9(4):R77. [PubMed: 17688691]

28. Ahn S-H, Cho Y-W, Ahn M-W, Jang SH, Sohn YK, Kim HS. mRNA expression of cytokines and chemokines in herniated lumbar intervertebral discs. *Spine*. 2002; 27(9):911–917. [PubMed: 11979160]
29. Akyol S, Eraslan BS, Etyemez H. Catabolic cytokine expressions in patients with degenerative disc disease. *Turk Neurosurg*. 2010; 20(4):492–499. [PubMed: 20963699]
30. Bachmeier BE, Nerlich AG, Weiler C. Analysis of tissue distribution of TNF-alpha, TNF-alpha-receptors, and the activating TNF-alpha-converting enzyme suggests activation of the TNF-alpha system in the aging intervertebral disc. *Ann N Y Acad Sci*. 2007; 1096:44–54. [PubMed: 17405915]
31. Dongfeng R, Hou S, Wu W. The expression of tumor necrosis factor- α and CD68 in high-intensity zone of lumbar intervertebral disc on magnetic resonance image in the patients with low back pain. *Spine*. 2011; 36(6):E429–E433. [PubMed: 21192298]
32. Lee S, Moon CS, Sul D. Comparison of growth factor and cytokine expression in patients with degenerated disc disease and herniated nucleus pulposus. *Clin Biochem*. 2009; 42(15):1504–1511. [PubMed: 19563795]
33. Park JY, Kuh SU, Park HS, Kim KS. Comparative expression of matrix-associated genes and inflammatory cytokines-associated genes according to disc degeneration: analysis of living human nucleus pulposus. *J Spinal Disord Tech*. 2011; 24(6):352–357. [PubMed: 21150669]
34. Weiler C, Nerlich AG, Bachmeier BE, Boos N. Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: a study in surgical specimen and autopsy controls. *Spine*. 2005; 30(1):44–53. discussion 54. [PubMed: 15626980]
35. Peng B, Hao J, Hou S. Possible pathogenesis of painful intervertebral disc degeneration. *Spine*. 2006; 31(5):560–566. [PubMed: 16508552]
36. Kim JH, Studer RK, Sowa GA, Vo NV, Kang JD. Activated macrophage-like THP-1 cells modulate anulus fibrosus cell production of inflammatory mediators in response to cytokines. *Spine*. 2008; 33(21):2253–2259. [PubMed: 18784630]
37. Takada T, Nishida K, Maeno K. Intervertebral disc and macrophage interaction induces mechanical hyperalgesia and cytokine production in a herniated disc model in rats. *Arthritis Rheum*. 2012; 64(8):2601–2610. [PubMed: 22392593]
38. Séguin CA, Pilliar RM, Roughley PJ, Kandel RA. Tumor necrosis factor-alpha modulates matrix production and catabolism in nucleus pulposus tissue. *Spine*. 2005; 30(17):1940–1948. [PubMed: 16135983]
39. Wang J, Markova D, Anderson DG, Zheng Z, Shapiro IM, Risbud MV. TNF- α and IL-1 β promote a disintegrin-like and metalloprotease with thrombospondin type I motif-5-mediated aggrecan degradation through syndecan-4 in intervertebral disc. *J Biol Chem*. 2011; 286(46):39738–39749. [PubMed: 21949132]
40. Tian Y, Yuan W, Fujita N. Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF- κ B. *Am J Pathol*. 2013; 182(6):2310–2321. [PubMed: 23602832]
41. Abe Y, Akeda K, An HS. Proinflammatory cytokines stimulate the expression of nerve growth factor by human intervertebral disc cells. *Spine*. 2007; 32(6):635–642. [PubMed: 17413467]
42. Ohba T, Haro H, Ando T. TNF-alpha-induced NF-kappaB signaling reverses age-related declines in VEGF induction and angiogenic activity in intervertebral disc tissues. *J Orthop Res*. 2009; 27(2):229–235. [PubMed: 18683887]
43. Purmessur D, Freemont AJ, Hoyland JA. Expression and regulation of neurotrophins in the nondegenerate and degenerate human intervertebral disc. *Arthritis Res Ther*. 2008; 10(4):R99. [PubMed: 18727839]
44. Kemp SWP, Webb AA, Dhaliwal S, Syed S, Walsh SK, Midha R. Dose and duration of nerve growth factor (NGF) administration determine the extent of behavioral recovery following peripheral nerve injury in the rat. *Exp Neurol*. 2011; 229(2):460–470. [PubMed: 21458449]
45. Sainoh T, Orita S, Miyagi M. Single intradiscal administration of the tumor necrosis factor-alpha inhibitor, etanercept, for patients with discogenic low back pain. *Pain Med*. 2016; 17(1):40–45. [PubMed: 26243249]

46. Tobinick E, Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. *Curr Med Res Opin.* 2004; 20(7):1075–1085. [PubMed: 15265252]
47. Cohen SP, Wenzell D, Hurley RW. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. *Anesthesiology.* 2007; 107(1):99–105. [PubMed: 17585221]
48. Lai A, Moon A, Purmessur D. Assessment of functional and behavioral changes sensitive to painful disc degeneration. *J Orthop Res.* 2015; 33(5):755–764. [PubMed: 25731955]
49. Lai A, Moon A, Purmessur D. Annular puncture with tumor necrosis factor-alpha injection enhances painful behavior with disc degeneration in vivo. *Spine J.* 2016; 16(3):420–431. [PubMed: 26610672]
50. Hughes PC, Tanner JM. The assessment of skeletal maturity in the growing rat. *J Anat.* 1970; 106(pt 2):371–402. [PubMed: 4315144]
51. Nakamae T, Ochi M, Olmarker K. Pharmacological inhibition of tumor necrosis factor may reduce pain behavior changes induced by experimental disc puncture in the rat: an experimental study in rats. *Spine.* 2011; 36(4):E232–E236. [PubMed: 21037531]
52. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. *J Neurosci Methods.* 1994; 53(1):55–63. [PubMed: 7990513]
53. Lai A, Chow DHK, Siu WS, Holmes AD, Tang FH. Reliability of radiographic intervertebral disc height measurement for in vivo rat-tail model. *Med Eng Phys.* 2007; 29(7):814–819. [PubMed: 17023188]
54. Masuda K, Aota Y, Muehleman C. A novel rabbit model of mild, reproducible disc degeneration by an annulus needle puncture: correlation between the degree of disc injury and radiological and histological appearances of disc degeneration. *Spine.* 2005; 30(1):5–14. [PubMed: 15626974]
55. Rutges JPHJ, Duit RA, Kummer JA. A validated new histological classification for intervertebral disc degeneration. *Osteoarthritis Cartilage.* 2013; 21(12):2039–2047. [PubMed: 24120397]
56. Lee M, Kim B-J, Lim EJ. Complete Freund's adjuvant-induced intervertebral discitis as an animal model for discogenic low back pain. *Anesth Analg.* 2009; 109(4):1287–1296. [PubMed: 19762759]
57. Sobajima S, Kompel JF, Kim JS. A slowly progressive and reproducible animal model of intervertebral disc degeneration characterized by MRI, X-ray, and histology. *Spine.* 2005; 30(1): 15–24. [PubMed: 15626975]
58. Elliott DM, Yerramalli CS, Beckstein JC, Boxberger JI, Johannessen W, Vresilovic EJ. The effect of relative needle diameter in puncture and sham injection animal models of degeneration. *Spine.* 2008; 33(6):588–596. [PubMed: 18344851]
59. Martin JT, Gorth DJ, Beattie EE, Harfe BD, Smith LJ, Elliott DM. Needle puncture injury causes acute and long-term mechanical deficiency in a mouse model of intervertebral disc degeneration. *J Orthop Res.* 2013; 31(8):1276–1282. [PubMed: 23553925]
60. Norcross JP, Lester GE, Weinhold P, Dahnert LE. An in vivo model of degenerative disc disease. *J Orthop Res.* 2003; 21(1):183–188. [PubMed: 12507597]
61. Boxberger JI, Auerbach JD, Sen S, Elliott DM. An in vivo model of reduced nucleus pulposus glycosaminoglycan content in the rat lumbar intervertebral disc. *Spine.* 2008; 33(2):146–154. [PubMed: 18197098]
62. Daly C, Ghosh P, Jenkin G, Oehme D, Goldschlager T. A review of animal models of intervertebral disc degeneration: pathophysiology, regeneration, and translation to the clinic. *Biomed Res Int.* 2016; 2016:5952165. 1-5952114. [PubMed: 27314030]
63. Singh K, Masuda K, An HS. Animal models for human disc degeneration. *Spine J.* 2005; 5(6 suppl):267S–279S. [PubMed: 16291123]
64. Lotz JC. Animal models of intervertebral disc degeneration: lessons learned. *Spine.* 2004; 29(23): 2742–2750. [PubMed: 15564923]
65. Kim J-S, Kroin JS, Li X. The rat intervertebral disk degeneration pain model: relationships between biological and structural alterations and pain. *Arthritis Res Ther.* 2011; 13(5):R165. [PubMed: 21996269]

66. Borenstein DG, O'Mara JW, Boden SD. The value of magnetic resonance imaging of the lumbar spine to predict low-back pain in asymptomatic subjects: a seven-year follow-up study. *J Bone Joint Surg Am.* 2001; 83-A(9):1306–1311. [PubMed: 11568190]
67. MacGregor AJ, Andrew T, Sambrook PN, Spector TD. Structural, psychological, and genetic influences on low back and neck pain: a study of adult female twins. *Arthritis Rheum.* 2004; 51(2): 160–167. [PubMed: 15077255]
68. Samartzis D, Karppinen J, Luk K, Cheung K. Baseline MRI characteristics in asymptomatic subjects as predictors for future first-time LBP episode. *Global Spine J.* 2012; 2(1 suppl):s-0032-1319911–s-0032-1319911.
69. Millward-Sadler SJ, Costello PW, Freemont AJ, Hoyland JA. Regulation of catabolic gene expression in normal and degenerate human intervertebral disc cells: implications for the pathogenesis of intervertebral disc degeneration. *Arthritis Res Ther.* 2009; 11(3):R65. [PubMed: 19435506]
70. Purmessur D, Walter BA, Roughley PJ, Laudier DM, Hecht AC, Iatridis J. A role for TNF α in intervertebral disc degeneration: a non-recoverable catabolic shift. *Biochem Biophys Res Commun.* 2013; 433(1):151–156. [PubMed: 23438440]
71. Hoyland JA, Le Maitre C, Freemont AJ. Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. *Rheumatology (Oxford).* 2008; 47(6):809–814. [PubMed: 18397957]
72. Walter BA, Purmessur D, Likhitpanichkul M. Inflammatory kinetics and efficacy of anti-inflammatory treatments on human nucleus pulposus cells. *Spine.* 2015; 40(13):955–963. [PubMed: 25893355]
73. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. *Clin Pharmacokinet.* 2007; 46(8):645–660. [PubMed: 17655372]
74. Zhang J-M, An J. Cytokines, inflammation, and pain. *Int Anesthesiol Clin.* 2007; 45(2):27–37. [PubMed: 17426506]
75. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. *Arthritis Res Ther.* 2005; 7(4):R732–R745. [PubMed: 15987475]
76. Liu B, Li H, Brull SJ, Zhang J-M. Increased sensitivity of sensory neurons to tumor necrosis factor alpha in rats with chronic compression of the lumbar ganglia. *J Neurophysiol.* 2002; 88(3):1393–1399. [PubMed: 12205160]
77. Cheng J-K, Ji R-R. Intracellular signaling in primary sensory neurons and persistent pain. *Neurochem Res.* 2008; 33(10):1970–1978. [PubMed: 18427980]
78. Andrade P, Visser-Vandewalle V, Hoffmann C, Steinbusch HWM, Daemen MA, Hoogland G. Role of TNF-alpha during central sensitization in preclinical studies. *Neurol Sci.* 2011; 32(5):757–771. [PubMed: 21559854]
79. Junger H, Sorkin LS. Nociceptive and inflammatory effects of subcutaneous TNFalpha. *Pain.* 2000; 85(1-2):145–151. [PubMed: 10692613]
80. Ozaktay AC, Kallakuri S, Takebayashi T. Effects of interleukin-1 beta, interleukin-6, and tumor necrosis factor on sensitivity of dorsal root ganglion and peripheral receptive fields in rats. *Eur Spine J.* 2006; 15(10):1529–1537. [PubMed: 16474945]
81. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain.* 2011; 152(3 suppl):S2–S15. [PubMed: 20961685]
82. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. *Br J Pharmacol.* 1992; 107(3):660–664. [PubMed: 1472964]
83. Hayashi S, Taira A, Inoue G. TNF-alpha in nucleus pulposus induces sensory nerve growth: a study of the mechanism of discogenic low back pain using TNF-alpha-deficient mice. *Spine.* 2008; 33(14):1542–1546. [PubMed: 18552668]
84. Binch ALA, Cole AA, Breakwell LM. Nerves are more abundant than blood vessels in the degenerate human intervertebral disc. *Arthritis Res Ther.* 2015; 17:370. [PubMed: 26695177]
85. Kras JV, Kartha S, Winkelstein BA. Intra-articular nerve growth factor regulates development, but not maintenance, of injury-induced facet joint pain & spinal neuronal hypersensitivity. *Osteoarthritis Cartilage.* 2015; 23(11):1999–2008. [PubMed: 26521746]

86. Sorge RE, Mapplebeck JCS, Rosen S. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. *Nat Neurosci*. 2015; 18(8):1081–1083. [PubMed: 26120961]
87. Mogil JS, Wilson SG, Chesler EJ. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. *Proc Natl Acad Sci U S A*. 2003; 100(8):4867–4872. [PubMed: 12663858]
88. Alini M, Eisenstein SM, Ito K. Are animal models useful for studying human disc disorders/ degeneration? *Eur Spine J*. 2008; 17(1):2–19. [PubMed: 17632738]




FIGURE 1. Induced intervertebral disc (IVD) injury illustration. Image created from Mount Sinai Health System. Used with permission

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




FIGURE 2.

Tumor necrosis factor-alpha (TNF α) inhibition at time of intervertebral disc (IVD) injury prevents development of acute and long-term painful behavior. A, Normalized paw withdrawal threshold by experimental group over time. Scatter plots presents the comparison of normalized withdrawal threshold across groups at B (acute [1-week postsurgery]) and C (long-term [6 weeks postsurgery]) time points. Data presented as mean \pm SD. # indicates $P < .05$ compared to presurgery baseline value. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$ by a one-way ANOVA with Tukey's post hoc




FIGURE 3.

Tumor necrosis factor-alpha (TNF α) inhibition at time of intervertebral disc (IVD) injury prevents IVD structural degeneration but not IVD height loss. A, Mid-sagittal sections stained with hematoxylin/safranin-O/light green. Boxed regions shown under higher magnification. B, IVD degeneration by group. C, Radiographic IVD height by group normalized to presurgery levels. Scale bars (whole IVD) = 500 μ m. Scale bars (annulus fibrosus [AF] and nucleus pulposus [NP]) = 100 μ m. Data presented as mean \pm SD. * P < .05, ** P < .01, *** P < .001, **** P < .0001 by a one-way ANOVA with Tukey's post hoc




FIGURE 4.

Tumor necrosis factor-alpha (TNF α) inhibition at time of intervertebral disc (IVD) injury prevents intradiscal TNF α upregulation at 6 weeks postsurgery. Representative anti-TNF α immunostained sections for A (annulus fibrosus) and B (nucleus pulposus). C, Quantified TNF α by group. Representative anti-interleukin (IL)-1 β immunostained sections for D (annulus fibrosus) and E (nucleus pulposus). F, Quantified IL-1 β by group. Green arrows denote immunopositive cells. Scatter plots presents the percentage of immunopositive cells for E (TNF α) and F (IL-1 β). Data presented as mean \pm SD. * P < .05, ** P < .01, # P < .10 by a one-way ANOVA with Tukey's post hoc




FIGURE 5.

Pain, structural parameters, and intradiscal pro-inflammatory cytokines correlate. A, Normalized paw withdrawal threshold vs intervertebral disc (IVD) degeneration. B, Normalized paw withdrawal threshold vs intradiscal tumor necrosis factor-alpha (TNF α) immunopositivity. C, Normalized paw withdrawal threshold vs intradiscal interleukin (IL)-1 β immunopositivity. D, IVD degeneration vs intradiscal TNF α immunopositivity. E, IVD degeneration vs intradiscal IL-1 β immunopositivity. F, Intradiscal TNF α immunopositivity vs intradiscal IL-1 β immunopositivity

TABLE 1Intervertebral disc (IVD) degeneration grading scale^a

Annulus fibrosus		
Grade	0	Normal, pattern of fibrocartilage lamellae (U-shaped in the posterior aspect and slightly convex in the anterior aspect) without ruptured fibers and without a serpentine appearance anywhere within the annulus
	1	Ruptured or serpentine pattern fibers in less than 30% of the annulus
	2	Ruptured or serpentine pattern fibers in greater than 30% of the annulus
Border between annulus fibrosus and nucleus pulposus		
Grade	0	Normal
	1	Minimally interrupted
	2	Moderate/severe interruption
Cellularity of nucleus pulposus		
Grade	0	Normal cellularity with large vacuoles in the gelatinous structure of the matrix
	1	Slight decrease in the number of cells and fewer vacuoles
	2	Moderate/severe decrease (>50%) in the number of cells and no vacuoles
Matrix of nucleus pulposus		
Grade	0	Normal gelatinous appearance
	1	Slight condensation of the extracellular matrix
	2	Moderate/severe condensation of the extracellular matrix
Endplate		
Grade	0	Homogenous structure; regular thickness
	1	Slight irregularity with limited number of microfractures; locally decreased thickness
	2	Severe irregularity with multiple microfractures of endplate; generalized decrease of thickness

^aThe scale is a combination of previously developed and validated IVD degeneration grading schemes.^{54,55}

TABLE 2

Painful behavior predicted by intervertebral disc (IVD) degeneration and intradiscal tumor necrosis factor-alpha (TNF α)^a

	Multivariate	
	β	P-value
IVD degeneration	-0.533	0.001
Intradiscal % TNF α positivity	-0.355	0.016
Intradiscal % interleukin-1 beta positivity	-0.048	0.777
Normalized IVD height	-0.026	0.876

β , standardized coefficient of variation. Bold indicates statistical significance.

^aRelationship of paw withdrawal threshold to structural IVD degeneration, IVD height, and intradiscal pro-inflammatory cytokines using multivariate stepwise linear regression.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 3

Pain, structural intervertebral disc (IVD) degeneration, and intradiscal pro-inflammatory cytokines correlate

		IVD degeneration	Normalized IVD height	% Intradiscal TNF α positivity	% Intradiscal L-1 β positivity
Normalized paw withdrawal threshold	<i>r</i> (<i>P</i>)	-0.694 (<0.001)	0.508 (0.002)	-0.562 (0.001)	-0.452 (0.011)
IVD degeneration	<i>r</i> (<i>P</i>)	1	-0.630 (<0.001)	0.476 (0.004)	0.351 (0.05)
Normalized IVD height	<i>r</i> (<i>P</i>)		1	-0.407 (0.017)	-0.466 (0.008)
% Intradiscal TNF α positivity	<i>r</i> (<i>P</i>)			1	0.674 (<0.001)

Abbreviations: IL-1 β , interleukin-1 beta; TNF α , tumor necrosis factor-alpha. Bold indicates significant correlations.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript